Trial Profile
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin glulisine (Primary) ; Insulin aspart; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PUMP
- Sponsors Sanofi
- 28 Jun 2012 Novo Nordisk and Eli Lilly added as associations as reported by European Clinical Trials Database.
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2009 Additional trial acronym (PUMP) identified as reported by ClinicalTrials.gov.